December 9, 2024 Experience Enviva emerges from chapter 11 We advised an ad hoc group of creditors in connection with Enviva’s chapter 11 proceedings
November 26, 2024 Experience Spirit Airlines prearranged chapter 11 filing We are advising Spirit Airlines in connection with entry into an RSA and negotiation of a prearranged chapter 11 plan
October 31, 2024 Experience Molecular Partners $20 million follow-on offering The ADSs are listed on the Nasdaq Global Select Market
October 18, 2024 Experience Inventiva private placement of up to €348 million The offering includes ordinary shares, pre-funded warrants and warrants
October 16, 2024 Experience Immatics $150 million follow-on offering We advised Immatics on the offering of shares
September 24, 2024 Experience Labcorp $2 billion senior notes offering The investment-grade notes are due 2030, 2032 and 2034
September 19, 2024 Experience Novartis $3.7 billion notes offering We advised Novartis on the investment-grade debt offering
September 16, 2024 Experience Terns Pharmaceuticals $173 million stock and pre-funded warrants offering The shares are listed on the Nasdaq Global Select Market
August 14, 2024 Experience Eli Lilly $5 billion notes offering The investment-grade notes are due 2027, 2029, 2034, 2054 and 2064
August 13, 2024 Experience ANI Pharmaceuticals $316.25 million convertible notes offering We advised ANI Pharmaceuticals on the offering